Hybio Pharmaceutical Co., Ltd. (300199.SZ) Bundle
Who's buying into Hybio Pharmaceutical and why the market is taking note: with a market capitalization of CNY 16.84 billion and a share price at CNY 19.07, institutional investors currently hold 1,235,100 shares (0.14%)-led by Vanguard's VGTSX with 839,100 shares (0.09%) while individual founder Li Wei alone controls 10% (36,000,000 shares) and China Life holds 8.50% (30,000,000 shares); Hybio's quarter-ended September 30, 2025 revenue was CNY 133.68 million (an 11.86% sequential rise) amid GMP-certified peptide and oligonucleotide production and a strategic tie-up with BrightGene to secure overseas supply chains, factors that accompany a 67.43% year-over-year market-cap climb to CNY 16.84 billion and an expected Q1 2025 net profit attributable to shareholders of CNY 60-72 million-details that explain recent shifts in institutional holdings and investor sentiment, so read on to unpack who's increasing exposure, how much they own, and what it means for Hybio's next chapter
Hybio Pharmaceutical Co., Ltd. (300199.SZ) - Who Invests in Hybio Pharmaceutical Co., Ltd. and Why?
Hybio Pharmaceutical Co., Ltd. (300199.SZ) attracts a mix of retail, founder, and institutional investors driven by its specialty in peptide and oligonucleotide therapeutics, GMP-certified production capacity, and recent quarter growth metrics.- Market capitalization: CNY 16.84 billion (as of September 15, 2025).
- Share price: CNY 19.07 (as of September 15, 2025).
- Institutional holdings: 1,235,100 shares, representing 0.14% of outstanding shares.
- Founder stake: Li Wei holds 10% of the company.
- Latest quarter revenue (Q3 2025 ending Sept 30): CNY 133.68 million, +11.86% QoQ.
- Vanguard Total International Stock Index Fund Investor Shares (VGTSX)
- Vanguard Total World Stock Index Fund ETF Shares (VT)
- SPDR S&P Emerging Markets Small Cap ETF (EWX)
- Strategic exposure: ETFs and index funds gain emerging-market/small-cap biotech exposure via listed shares.
- Growth potential: accelerating quarterly revenue (+11.86% QoQ) suggests commercial traction.
- Product focus: peptide and oligonucleotide drug platforms address niche, high-margin therapeutic areas.
- Manufacturing advantage: GMP-certified facilities that meet international standards reduce scale-up and CMC risks.
- Insider alignment: Li Wei's 10% ownership signals founder/alignment with shareholder value creation.
| Metric | Value |
|---|---|
| Market Cap (15 Sep 2025) | CNY 16.84 billion |
| Share Price (15 Sep 2025) | CNY 19.07 |
| Institutional Shares | 1,235,100 shares (0.14% outstanding) |
| Founder Ownership | Li Wei - 10% |
| Q3 2025 Revenue (ended 30 Sep) | CNY 133.68 million |
| QOQ Revenue Growth (Q3 2025) | +11.86% |
| Core R&D/Production Focus | Peptide & oligonucleotide therapeutics; GMP-certified production |
Hybio Pharmaceutical Co., Ltd. (300199.SZ) Institutional Ownership and Major Shareholders of Hybio Pharmaceutical Co., Ltd. (300199.SZ)
As of September 15, 2025, institutional investors collectively hold 0.14% of Hybio Pharmaceutical Co., Ltd.'s outstanding shares, totaling 1,235,100 shares. Institutional positions are small relative to major strategic and individual holders, reflecting a shareholder base dominated by concentrated large stakes and retail/insider ownership.- Total institutional holdings: 1,235,100 shares (0.14% of outstanding)
- Vanguard Total International Stock Index Fund Investor Shares (VGTSX): 839,100 shares (0.09%)
- Vanguard Total World Stock Index Fund ETF Shares (VT): 43,100 shares (0.005%)
- SPDR S&P Emerging Markets Small Cap ETF (EWX): 56,000 shares (0.006%)
- Li Wei (individual investor): 36,000,000 shares (10.00% - largest single shareholder)
- China Life Insurance Co., Ltd.: 30,000,000 shares (8.50% - major institutional strategic investor)
| Shareholder | Shares Held | Stake (%) | Type |
|---|---|---|---|
| Li Wei | 36,000,000 | 10.00% | Individual / Insider |
| China Life Insurance Co., Ltd. | 30,000,000 | 8.50% | Institutional / Strategic |
| Vanguard Total International Stock Index Fund (VGTSX) | 839,100 | 0.09% | Passive Institutional |
| SPDR S&P Emerging Markets Small Cap ETF (EWX) | 56,000 | 0.006% | Passive ETF |
| Vanguard Total World Stock Index Fund (VT) | 43,100 | 0.005% | Passive ETF |
| Other institutions (aggregate) | 266,900 | 0.035% | Institutions |
- Concentrated control: Large individual and insurance-company stakes (Li Wei and China Life) create stability in strategic decision-making and deter dispersion-driven activism.
- Passive international allocations: Funds like VGTSX and VT hold small passive positions likely due to index inclusion and emerging-market exposure rather than active conviction.
- Small-cap EM ETF exposure: EWX's position aligns with thematic exposure to China small-cap pharmaceuticals rather than company-specific thesis.
Key Investors and Their Impact on Hybio Pharmaceutical Co., Ltd. (300199.SZ)
Hybio Pharmaceutical Co., Ltd. (300199.SZ) shows a shifting shareholder base that blends passive global funds, active institutional investors and large strategic individual stakes - each affecting liquidity, governance expectations and market perception.
- Vanguard Total International Stock Index Fund Investor Shares (VGTSX): increased holdings by 22,000 shares to 839,100 shares as of June 30, 2025 - signaling steady passive/ETF-driven demand from global equity allocations.
- SPDR S&P Emerging Markets Small Cap ETF (EWX): increased holdings by 56,000 shares to 56,000 shares as of August 28, 2025 - indicating new or materially expanded exposure from an emerging‑market small‑cap strategy.
- Individual investor Li Wei: holds ~10% of issued shares - a sizable concentrated stake that reflects high conviction and provides a potential long‑term stabilizing influence.
- China Life Insurance Co., Ltd.: holds an 8.50% stake - significant institutional ownership that signals confidence from a large domestic insurer and may drive engagement on corporate strategy.
| Investor | Reported Holding Change | Total Shares Held (reported date) | Approx. Ownership (%) |
|---|---|---|---|
| VGTSX (Vanguard Total International Stock Index Fund Investor Shares) | +22,000 shares | 839,100 (as of 2025-06-30) | - (passive fund position) |
| EWX (SPDR S&P Emerging Markets Small Cap ETF) | +56,000 shares | 56,000 (as of 2025-08-28) | - (ETF small‑cap allocation) |
| Li Wei (individual) | - | - | ≈10% |
| China Life Insurance Co., Ltd. | - | - | 8.50% |
Key implications for Hybio's investor profile:
- Growing institutional and ETF holdings increase free‑float and trading liquidity, potentially narrowing bid‑ask spreads and enabling larger block trades.
- Presence of large concentrated holders (Li Wei, China Life) raises the probability of active engagement on strategic initiatives, board representation or long‑term support during R&D cycles.
- New ETF exposure (EWX) can attract additional quant and index‑tracking flows, while VGTSX additions reflect inclusion in broad international allocations.
- Strategic cooperation with BrightGene Pharmaceutical to safeguard overseas supply chains for innovative drugs strengthens operational risk mitigation - a factor likely contributing to institutional confidence in Hybio's peptide and oligonucleotide portfolio.
For financial metrics, governance detail and a deeper look at how these holdings intersect with Hybio's balance sheet and R&D runway, see: Breaking Down Hybio Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors
Hybio Pharmaceutical Co., Ltd. (300199.SZ) - Market Impact and Investor Sentiment
The market responded strongly to Hybio Pharmaceutical Co., Ltd. (300199.SZ) as the company's market capitalization rose 67.43% year-over-year to CNY 16.84 billion as of December 12, 2025, implying a prior market cap of roughly CNY 10.06 billion. That jump, combined with improving quarterly revenue and a projected return to profitability, has materially shifted investor sentiment.- Market-cap change: +67.43% YoY to CNY 16.84 billion (Dec 12, 2025).
- Quarterly revenue (Q3 2025): CNY 133.68 million, +11.86% QoQ.
- Q1 2025 net profit attributable: expected CNY 60-72 million (turnaround from prior-year weakness).
- Strategic cooperation with BrightGene Pharmaceutical to secure overseas supply chains for innovative drugs.
- Focus areas: peptide and oligonucleotide therapeutics with GMP-certified, internationally compliant production facilities.
| Metric | Value | Notes |
|---|---|---|
| Market Capitalization (12-Dec-2025) | CNY 16.84 billion | +67.43% YoY |
| Implied Market Cap (prior year) | CNY ~10.06 billion | Derived from YoY increase |
| Revenue (Q3 2025) | CNY 133.68 million | +11.86% QoQ |
| Revenue (Q2 2025, implied) | CNY ~119.45 million | Calculated from QoQ growth |
| Net Profit Attributable (Q1 2025, expected) | CNY 60-72 million | Significant turnaround vs. same period prior year |
| Strategic Partner | BrightGene Pharmaceutical | Overseas supply-chain cooperation |
| Core Therapeutic Focus | Peptides & oligonucleotides | GMP-certified production, international standards |
- Improving top-line momentum: sequential revenue growth and restored profitability expectations.
- Risk mitigation via supply-chain partnerships (BrightGene) that reduce commercialization uncertainty for innovative assets.
- Institutional interest rising alongside positive financial indicators and clearer growth pathways in specialty biologics.
Hybio Pharmaceutical Co., Ltd. (300199.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.